Genetic polymorphisms and response to clopidogrel and risk of cardiovascular events

Across the whole spectrum of acute coronary syndromes and in patients undergoing PCI and stenting, dual anti-platelet therapy with aspirin and clopidogrel is the current recognised standard of care. However, significant variation in response to clopidogrel is observed between patients, with those with lesser degrees of platelet inhibition being at higher risk of adverse cardiovascular […]

Read More…

Lp-PLA2 Inhibiton Decreases Complex Plaque Development

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that is produced by inflammatory cells in atherosclerotic lesions.  It has previously been shown to be present at higher levels in the core of ruptured atherosclerotic plaques, although it was unclear whether this was merely an association or whether the enzyme played a key role in plaque vulnerability. […]

Read More…

Short telomere length associated with family history of premature myocardial infarction

Telomeres are specialised DNA-protein structures at the end of chromosomes, and are vital to preserve chromosome integrity and stability.  Telomeres are known to shorten with age, but prematurely shortened telomeres have been found in cells from human atherosclerotic plaques, and a previous relationship between telomere length and coronary artery disease has been described. […]

Read More…

Metabolic assays of ischaemia show early promise

Metabolic technologies allow the profiling of low-molecular weight biochemicals such as amino acids, sugars, and lipids that are substrates and products in important biological processes, such as ischaemia.  To examine whether this techology could be used to allow earlier detection of myocardial ischaemia and infarction, Lewis et al. applied mass spectrometry-based metabolite profiling to 36 […]

Read More…